Dr. Lars Behrend joins SSS International Clinical Research and expands the executive board.
Germering near Munich, Germany, August 03, 2017. SSS International Clinical Research GmbH (SSS), an innovative and flexible partner for European-wide clinical studies, continues to expand. As of now, the founder, Dr. Michael Sigmund and the new Chief Operating Officer (COO), Dr. Lars Behrend, will be working hand-in-hand to rapidly implement the international growth strategy. The new addition to the executive board meets the needs of the growth strategy and guarantees the well-known pharmaceutical industry customers full cooperation together with a strong and long-term partner.
For more than 20 years, SSS has been successful within the area of clinical contract research (Full Service Contract Research) for the development of medicines and medical products. For further process professionalization and the development of the three subsidiaries in Germany, Poland and Romania, Dr. Michael Sigmund, until now the sole CEO of the company, has decided to bring reinforcements on board to create a future-orientated executive management.
From July 2017, Dr. Lars Behrend (45) will fill the role of COO, covering the key areas of financial management, controlling and business development. Lars Behrend holds a diploma in biology and a PhD in cancer research. He has 15 years work experience in management and consulting within the medical sector, biotechnology and cleantech areas.
“Having Dr. Lars Behrend on the team is a real stroke of luck. Here is a person who not only has extensive experience as a management executive and knows all about the clinical and biotechnology sectors. He also has a real entrepreneurial personality with hands-on experience in developing professional organisational structures and knowing the importance of cooperative customer relationships.” comments Dr. Michael Sigmund the personnel decision. “I have gained a sparring partner who exactly knows the critical phase when medicines move from theoretical research to the clinic. In future, I can concentrate more on the strategic development of our company.”